Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising.
MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF), a biotechnology company commercializing AI-driven voice analytics for drug and alcohol intoxication detection, is expanding its artificial intelligence-based intoxication detection platform with the rollout of Intox Collect(TM), a new software tool designed to broaden the company’s data collection and analytics capabilities across a wider range of substances that affect the central nervous system.
The company said the newly completed software enhances its ability to collect and process voice and facial recognition data related to intoxication from stimulants and depressants, building on its core technology platform focused on detecting alcohol and drug impairment through speech analysis.
The announcement marks a strategic expansion for MindBio as it seeks to broaden the applicability of its artificial intelligence models beyond alcohol detection and further into enterprise and institutional markets where rapid impairment testing may have commercial and regulatory relevance.
MindBio has spent several years developing AI-powered predictive models aimed at estimating intoxication using human voice data. The company states that its proprietary AI model has been trained using more than 50 million data points, enabling the system to identify intoxication patterns based on vocal biomarkers alone. Management expects that database to expand significantly in the coming months as data collection accelerates.
With Intox Collect(TM), MindBio says it can now scale the collection and analysis of voice and facial recognition data across a broader set of intoxicating substances, not just alcohol. That may increase the platform’s utility in industries where employers and regulators require testing for multiple categories of impairing substances, including narcotics, stimulants and prescription medications.
Management has framed the software as a means of accelerating model training and improving detection capabilities across substances that impair cognition, reaction time and workplace performance.
The company’s broader thesis centers on the practical challenges associated with conventional intoxication testing. Traditional workplace drug and alcohol screening often relies on breathalyzers, saliva swabs, blood testing or urine collection; methods that can be time-consuming, physically invasive and operationally disruptive, particularly in large industrial environments. MindBio is attempting to offer an alternative: AI-based screening conducted through voice and visual analysis.
The company believes such technology may be useful in sectors where high-volume testing is mandated or operationally necessary, particularly in safety-sensitive industries such as mining, aviation, construction and transportation. Those sectors face increasing regulatory and insurance scrutiny over impairment-related accidents, and employers often seek methods of reducing workplace risk while minimizing downtime.
According to MindBio, the company’s platform may provide a faster and less intrusive way to conduct screening at scale, particularly where large workforces require regular intoxication monitoring.
MindBio’s software expansion comes as the company also advances the hardware side of its commercialization strategy. The company recently stated that development of its Edge AI hardware-software platform is nearing completion, with prototype kiosk devices expected to be ready for testing in late Q2 2026.
These kiosk-based systems are intended to integrate the company’s AI models into touchscreen terminals capable of enterprise deployment at worksites, checkpoints or facility entrances. Under the proposed model, individuals would provide a voice sample, and potentially facial input, for real-time analysis before entering a workplace or secure environment.
The kiosk platform is being developed as a primary enterprise product for industrial and institutional customers. MindBio has said the hardware initiative is supported by a recently completed financing round that raised up to $1.5 million in private placement proceeds.
“The digital health diagnostics market represents a significant opportunity for MindBio to leverage its diagnostics technology with a first mover advantage in speech analytics for drug and alcohol intoxication detection,” said CEO Justin Hanka. “Our technology gives us a significant advantage in using voice to develop non-invasive health diagnostic tools”.
For more information, visit the company’s website at www.MindBioTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
BioMedWire Editorial Coverage: Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how…
Designations from established global organizations such as the European Commission carry meaningful implications for biotechnology…
Targeted cancer therapies are increasingly being paired with immunotherapy and chemotherapy to improve outcomes across…
A survey that was conducted toward the end of last year by Gallup and West…
Soligenix reports clinical update centered on cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin…
Lung cancer is the leading cause of cancer-linked fatalities among men and women, and survival beyond five…